The APIC Audit Programme
|
|
|
- Naomi Kathlyn Allen
- 9 years ago
- Views:
Transcription
1 The APIC Audit Programme Standardised Cost APIC-certified GMP Compliance A Third Party Audit Programme for API Manufactureres An Initiative of APIC in co-operation with CONCEPT HEIDELBERG A sector group of Coordinated by API Compliance Institute
2 Necessity for API Manufacturers to Comply with cgmp for APIs - Legal Background - According to the US Food and Drug Law the manufacturer of active pharmaceutical ingredients (APIs) has to comply with the current Good Manufacturing Practices, and the manufacture of APIs is object of FDA inspections. The legal situation in Europe is different: From 30 October 2005 on, cgmp for APIs used in the manufacture of human and/or veterinary medicinal products will be required by law in Europe, but authority inspections at the premises of API manufacturers will only be carried out whenever grounds for suspecting non-compliance with the principles and guidelines of GMP are considered. On the other hand, a competent authority of an EU Member State must be able to satisfy itself that the manufacture and distribution of active substances has been carried out in accordance with the principles of GMP for APIs. According to a recently published EMEA draft guidance, it is therefore planned that when applying for a marketing authorisation (or a variation to change or add a new active substance manufacturer) the applicant has to submit a declaration from the manufacturing authorisation holder that the API concerned has been manufactured according to the GMP for APIs. The competent authorities expect that the manufacturing authorisation holder will base such a declaration on carrying out or having carried out on an audit of the manufacturers/distributors of the active substances concerned. One of the primary means by which the competent authorities will determine whether manufacturing authorisation holders are in compliance with the above articles will be the examination, by inspectors, of the audit programmes used by authorisation holders for conducting regular audits (every 2-3 years), including review of audit reports (see Draft Guidance on the occasions when it is appropriate for Competent Authorities to conduct inspections at the premises of Manufacturers of Active Substances used as starting materials, Doc.Ref. EMEA/INS/GMP/50288/2005 from 02 March 2005). What is the APIC Audit Programme? The APIC Audit Programme is a third party audit programme for auditing API manufacturers, distributors and API contract manufacturers and/or contract laboratories. This programme was developed by APIC/CEFIC in cooperation with CONCEPT HEIDELBERG It is the aim of the APIC Audit Programme to offer an independent and turnkey GMP Compliance audit of API manufacturers and/or distributors, including organization, conduct and evaluation of the audit. An APIC Audit within the framework of the APIC Audit Programme can be initiated by an API manufacturer or distributor in order to get independent information about the GMP compliance status, e.g. when preparing for authority inspections. It can also be initiated by the manufacturing authorization holder (the pharmaceutical company) for carrying out audits on its
3 behalf in order to fulfil the requirements of the European Legislation. APIC audits will be conducted worldwide. The participation in the APIC Audit Programme is on voluntary basis and not limited to members of APIC. How can GMP audits be standardised? There are three basic principles of the APIC Audit Programme for standardizing audits: experienced and trained auditors that are registered as APIC certified auditors standardised process for preparing audits release of audit report by experienced API specialists The audits are conducted by APIC certified auditors who have the professional experience, who have completed an ICH Q7a compliance education course and a special APIC Auditor Training who have participated in regular auditor refresher seminars who have signed a contract laying down the obligations as an auditor in the framework of the APIC Audit Programme The audits are conducted on the basis of the ICH Q7a (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients) with regard to the APIC Auditing Guide. Save money and optimise the GMP Audit The aims of The APIC Audit Programme are: standardised GMP audits of API manufacturers minimised costs by - decreasing the frequency of audits when making the audit report available to pharmaceutical companies - standardized costs for audits Will Third Party Audits be Accepted by the Authorities? An audit is an important tool for evaluating GMP compliance. A frequently asked question in connection with the APIC Audit Programme is whether a third arty audit will be accepted by the authorities. According to a recently published draft Guidance on the occasions when it is appropriate for Competent Authorities to conduct inspections at the premises of Active Substances used as starting materials it is expected that the holder of the manufacturing authorization will base such a declaration *) on carrying out, or having carried out on his behalf, an audit of the manufacturers/distributors of the active substances concerned.
4 This clearly states that third party audits are being accepted. Similar third party programmes have already been established in other areas: ARC (Audit Repository Center), a PDA-associated company, offers auditing programmes for the audit of software suppliers, the IPEC (International Pharmaceutical Excipients Council) provides Third Party Auditing Programmes for excipient suppliers. With regard to the acceptance of Third Party Audits IPEC member Irwin Silverstein said "lawyer with both industry and FDA experience have been involved in developing the program and (that) nobody has raised a concern that the third party audit would present more of a problem than having your own people do the same audit". (Gold Sheet, Vol 34, No. 1, January 2000). *) A declaration from the manufacturing authorization holder that the active substance(s) concerned has(have) been manufactured in accordance with the detailed guidelines on good manufacturing practice for starting material. Who Coordinates the APIC Audit Programme? The APIC Audit Programme will be coordinated by the API Compliance Institute. The API Compliance Institute was founded on 19 December The basis for the activities of the API Compliance Institute is constituted by a contractual agreement between APIC, a sector group of CEFIC, and CONCEPT HEIDELBERG. It is the mission of the API Compliance Institute to standardize GMP audits of API manufacturers and to minimize the costs. For further information about the APIC Audit Programme, please visit the web page of the API Compliance Institute. The APIC Audit Programme - Step by step - A GMP audit can be initiated by but is not limited to: Manufacturers of active pharmaceutical ingredients as well as - Agents, brokers, distributors, repackers and relabellers of APIs - Contract manufacturers of API manufacturers - Contract laboratories of API manufacturers Pharmaceutical companies that manufacture either medicinal products for human use or veterinary medicinal products in order to fulfil their obligations according to Directives 2001/83/EC and 2001/82/EC as amended.
5 The following flow chart describes the steps from the initial contact with the company (auditee) to the finalisation of the audit report. IMPORTANT: As the APIC Audit Programme is a worldwide third party auditing programme. The audits will be conducted in English and the Audit Report will be written in English.
6 Preliminary Talks Before placement of an order by an interested customer the API Compliance Institute will have preliminary talks on the following topics, among others: Scope of the audit, steps of the audit process, expected time inputs and expected costs, etc. Provided the customer signed a contract with the API Compliance Institute the order is considered awarded an the further steps can be followed. Preparation for the Audit For gaining initial information about the company (auditee) and to effectively plan the audit a questionnaire will be sent to the company (auditee) in advance. After return of the completed questionnaire to the API Compliance Institute, auditors will be selected upon the information given in the questionnaire. The questionnaire will also be handed on to the selected auditors for their preparation. The company (auditee) will appoint a contact person (audit representative) responsible for the handling of the audit. Selection of APIC Certified Auditors In general, the APIC Compliance Institute will select two certified auditors from their register. The company (auditee) will be notified of the names of the auditors. The company (auditee) is entitled to reject the appointed auditors, but will be asked to explain the reasons for rejecting the auditor. In these cases new auditors are going to be selected. Preparation and Execution of the Audit Before the audit the company (auditee) will receive an audit plan from the auditors, detailing the major topics of the audit and a tentative schedule. Immediately after the audit all major observations and remaining questions will be discussed and clarified during the final wrap up. If, for any reason, a re-audit of follow-up audit deems to be necessary, the date for the re- (follow-up) audit as well a s the selection of the auditors will be set by the API Compliance Institute. An additional order is required. Finalizing the Audit Report At the latest, within a period of 4 weeks after the audit, the company (auditee) will receive a draft audit report. The audit report will include a management summary as well as a detailed list of observations. The company (auditee) may respond to the observations, proposing corrective actions, responsibilities and time frames. The final audit report is being released by APIC before sending it to the company (auditee). The company (auditee) will receive the original audit report for use without limitations.
7 The Auditors In general, the audits will be conducted by two auditors who are registered as APIC certified auditors. APIC certified auditors will undergo extensive training programmes as described on page 2 of this brochure and have to verify their professional experience. APIC will authorise a register of certified auditors who are allowed to conduct the audits within the framework of the APIC Audit Programme. Validity The basic audit report is valid for three years. Prior to the expiration, a new audit for the renewal of the validity can be carried out at the company s (auditee s) site. Costs The average costs for a GMP Audit conducted by two qualified APIC auditors will be EURO 8.400,-- plus VAT, plus travel expenses. Contact If you are interested in joining The APIC Audit Programme, please contact us for further information: Dr Barbara Jentges P.O. Box Heidelberg, Germany Phone +49-(0) Fax +49-(0) [email protected] OR Mr Pieter van der Hoeven, CEFIC Active Pharmaceutical Ingredients Committee (APIC) Av. E. Van Nieuwenhuyse 4 / box Brussels, Belgium Phone Fax [email protected]
8
Audit Report in the framework of the APIC Audit Programme
Audit Report in the framework of the APIC Audit Programme Company Location Address Country Subject of Audit Audit Date Auditor (lead) Co-Auditor(s) Participants Signature of Auditor(s) Lead Auditor Co-Auditor
Author General Management Quality Assurance
Lab Ofichem B.V. Pag.: 1 / 14 Date: 20-01- Version: 02 Status: geldig Contents 1. General... 2 2. Shared Third Party audit program... 3 3. Reassurance absence of Conflict of Interest... 5 4. Contract structure...
Guidance for Industry: Starting Material Supplier Management
Guidance for Industry: Starting Material Supplier Management Version 1.0 Drug Office Department of Health. Contents 1. Introduction... 3 2. Purpose of this document... 3 3. Scope... 3 4. Selecting and
Title:: Effective GMP AUDITS for APIs and Formulation Pharma Companies By G.Sundar-Director/Consultant PharmQA Compliance solutions
WELCOME Title:: Effective GMP AUDITS for APIs and Formulation Pharma Companies By G.Sundar-Director/Consultant PharmQA Compliance solutions Contents: Introduction GMP Audit GMP Audit plan GMP Auditing
QUALITY SYSTEM REQUIREMENTS FOR PHARMACEUTICAL INSPECTORATES
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 002-3 25 September 2007 RECOMMENDATION ON QUALITY SYSTEM REQUIREMENTS FOR PHARMACEUTICAL INSPECTORATES PIC/S September
Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE
Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Dr. Fulvio CARLOTTI, GNOSIS SpA, Corporate QA Director September 26, 2014 Scope of GMP GMP compliance
How companies leverage quality and quality certifications to achieve competitive advantage
How companies leverage quality and quality certifications to achieve competitive advantage Eize de Boer Systems & Services Certification International Business Development Manager Pharma Supply Chain for
Auditing as a Component of a Pharmaceutical Quality System
Auditing as a Component of a Pharmaceutical Quality System Tim Fields Conducting internal audits (or self inspections) and external audits of suppliers and outsourcing operations are key elements of a
CONCEPT HEIDELBERG. Pharmaceutical Quality Training. Conferences. Services.
CONCEPT HEIDELBERG Pharmaceutical Quality Training. Conferences. Services. About Us Helping you to Comply with GMP Since our foundation on 1 April 1978, CONCEPT HEIDELBERG has been concentrating on providing
EDQM Certificates of Suitability: Cooperation Among Inspectorates in Europe And Beyond
EDQM Certificates of Suitability: Cooperation Among Inspectorates in Europe And Beyond 14 th International Conference of Drug Regulatory Authorities Pre-ICDRA Meeting Dr Susanne Keitel European Directorate
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY VERSION 7
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Health systems and products Medicinal products quality, safety and efficacy Brussels, IMPORTATION OF ACTIVE SUBSTANCES FOR MEDICINAL PRODUCTS
Working Party on Control of Medicines and Inspections. Final Version of Annex 16 to the EU Guide to Good Manufacturing Practice
Version 8 (final) EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals and cosmetics Brussels, July 2001 S\common\legal-legislation\75-319nd81-851\91-356\eudralexvol4\Annex
Recent Updates on European Requirements and what QPs are expected to do
Recent Updates on European Requirements and what QPs are expected to do QP Forum 28/29 November 2013, Lisbon Dr. Bernd Renger Modified: Georg Goestl 1 Written Conformation for API-Import Actual Status
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL VERSION 4.1
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products quality, safety and efficacy Brussels, SANCO/D/6/SF/mg/ddg1.d.6(2013) IMPORTATION OF ACTIVE SUBSTANCES
20-21 May 2015, Lisbon, Portugal. Highlights. Speakers:
Speakers: Dr Afshin Hosseiny Chair of the ECA Expert Working Group on GDP, Tabriz Consulting Comply with the new EU GDP Guideline Dr Martin Egger Pharmaserv Dr Daniel Müller GMP/GDP Inspector All participants
Electronic GMP Systems
Electronic GMP Systems Specification - Implementation Validation 18 20 March 2015, Prague, Czech Republic SPEAKERS: Kai Kiefer fme AG, Germany Dr Bob McDowall McDowall Consulting, UK LEARNING OBJECTIVES:
PharmAssess Audit Reports Operational Consultancy GMP Auditing Services Regulatory Affairs. www.rephine.com
PharmAssess Audit Reports Operational Consultancy GMP Auditing Services Regulatory Affairs www.rephine.com The Market Leader in GMP Audit Reporting PharmAssess audit reports are accepted by all Regulatory
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products- authorisations, European Medicines Agency Brussels, EudraLex The Rules Governing Medicinal
The Quality System for Drugs in Germany
The Quality System for Drugs in Germany Prof. Dr. Harald G. Schweim Head of Department for Drug Regulatory Affairs Institute for Pharmacy, University of Bonn Former President of the German Federal Institute
Work plan for GMP/GDP Inspectors Working Group for 2016
21 December 2015 EMA/INS/GMP/738756/2015 Compliance and Inspection Work plan for GMP/GDP Inspectors Working Group for 2016 Chairperson: Status David Cockburn January 2016 1. Meetings scheduled for 2016
GMP Pharma BV. Netherlands
GMP Pharma BV Netherlands Connecting the European & Indian Pharmaceutical, Biotechnology and Biopharmaceutical Industry for parallel growth and solicitation. About Us: GMP Pharma BV is a multisource organization
GUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs.
15 January 2007 GUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs.) TABLE OF CONTENTS 1 INTRODUCTION... 2 2
The certification process
TS004(COS)v01 The certification process for COSMOS standard Standard in force available on www.cosmos-standard.org or sent on request. 1 Contents I. When to apply... 3 II. The different steps in the certification
QUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES
QUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES Why are Pharmacopoeias so important in a globalised world? Pharmacopoeias have historically provided collections of medical recipes intended to ensure accurate
COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP)
European Medicines Agency Veterinary Medicines and Inspections London, 15 April 2005 EMEA/CVMP/134/02 Rev 1 CPMP/QWP/227/02 Rev 1 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY
Guideline on good pharmacovigilance practices (GVP)
1 2 20 February 2012 EMA/541760/2011 3 4 Guideline on good pharmacovigilance practices (GVP) Module I Pharmacovigilance systems and their quality systems Draft finalised by the Agency in collaboration
Schweppes Australia Head Office Level 5, 111 Cecil Street South Melbourne Victoria 3205. www.schweppesaustralia.com.au
Schweppes Australia Head Office Level 5, 111 Cecil Street South Melbourne Victoria 3205 www.schweppesaustralia.com.au Quality Management Systems 1. Quality Management Systems develop, implement, verify
Adoption by GCP Inspectors Working Group for consultation 14 June 2011. End of consultation (deadline for comments) 15 February 2012
10 December 2013 EMA/INS/GCP/600788/2011 Compliance and Inspection Reflection paper on the use of interactive response technologies (interactive voice/web response systems) in clinical trials, with particular
Guideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/541760/2011 Guideline on good pharmacovigilance practices (GVP) Module I Pharmacovigilance systems and their quality systems Draft finalised by the Agency in collaboration with Member
COMMISSION DIRECTIVE 2003/94/EC
L 262/22 COMMISSION DIRECTIVE 2003/94/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal
GMP Issues for Start-Ups, quality in the supply chain and role of the Qualified Person (QP)
GMP Issues for Start-Ups, quality in the supply chain and role of the Qualified Person (QP) Presented by: Patrick Costello Scientific Administrator, European Medicines Agency An agency of the European
Audit of the control body through the monitoring of compliance with control plan. Measures for the irregularities
Workshop on verification of compliance with product specification for PDO, PGI and TSG Audit of the control body through the monitoring of compliance with control plan Measures for the irregularities Viktorija
Computerised Systems in Analytical Laboratories
ECA Certified Computer Validation Manager Course* New EU Annex 11 and Chapter 4 Requirements will be covered Computerised Systems in Analytical Laboratories Foto: DRK The Electronic Analytical GMP : Integrating
Compilation of Community Procedures on Inspections and Exchange of Information
EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE- GENERAL Public Health and Risk Assessment Pharmaceuticals 3 October 2014 EMA/572454/2014 Rev 17 Compliance and Inspection Compilation of Community
Disclaimer. The present document is an internal document that outlines the procedure as currently envisaged by the Commission.
Disclaimer The present document is an internal document that outlines the procedure as currently envisaged by the Commission. It is made available only for advance information and will be integrated into
2014 Annual Report on Inspections of Establishments
2014 Annual Report on Inspections of Establishments Table of Contents Introduction... 2 Data Collection and Definitions... 3 Section 510(h)(6)(A)(i) Number of Domestic and Foreign Establishments Registered
Pursuant to Convention No. 108 of the Council of Europe for the protection of persons with regard to the automated processing of personal data;
Decision No. 2011-316 dated 6 October 2011 adopting a standard for delivering privacy seals in audit procedures covering the protection of persons with regard to the processing of personal data The French
Working Party on Control of Medicines and Inspections. Final Version of Annex 15 to the EU Guide to Good Manufacturing Practice
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals and cosmetics Brussels, July 2001 Working Party on Control
PHARMACEUTICAL QUALITY SYSTEM Q10
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE PHARMACEUTICAL QUALITY SYSTEM Q10 Current Step
FAMI-QS Certification Rules for Operators. Rules for Operators
Rules for Operators TABLE OF CONTENTS 1. Application for certification and FAMI QS associate membership...2 2. Assessment of operators...3 2.1. Audit planning...3 2.2. Frequency of audits and re certification...5
Spillemyndigheden s Certification Programme Change Management Programme
SCP.06.00.EN.1.0 Table of contents Table of contents... 2 1 Objectives of the change management programme... 3 1.1 Scope of this document... 3 1.2 Version... 3 2 Certification... 4 2.1 Certification frequency...
PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013)
January 2013 RESTRICTED PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013) DRAFT FOR COMMENTS Please address any comments on this proposal
Spillemyndigheden s change management programme. Version 1.3.0 of 1 July 2012
Version 1.3.0 of 1 July 2012 Contents 1 Introduction... 3 1.1 Authority... 3 1.2 Objective... 3 1.3 Target audience... 3 1.4 Version... 3 1.5 Enquiries... 3 2. Framework for managing system changes...
Staying Current in Cold Chain Management
Staying Current in Cold Chain Management Changes to USP, EU GDPs and Storage and Shipping Practices for Drugs Table of Contents AUTHORS...3 Paul Daniel...3 Piritta Maunu...3 EDITOR...3 John Ferreira...3
The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers.
Supplier Quality Standard 1.0 Purpose The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers. These expectations
QSS 0: Products and Services without Bespoke Contracts.
QSS 0: Products and Services without Bespoke Contracts. Amendment History Version Date Status v.1 Dec 2014 Updated For 2015 deployment Table of Contents 1. DEFINITIONS 3 2. INTRODUCTION 3 3. WORKING WITH
ICH guideline Q10 on pharmaceutical quality system
September 2015 EMA/CHMP/ICH/214732/2007 Committee for Human Medicinal Products Step 5 Transmission to CHMP May 2007 Transmission to interested parties May 2007 Deadline for comments November 2007 Final
Certification Procedure of RSPO Supply Chain Audit
: 1 of 19 Table of Contents 1. Purpose 2. Scope 3. Unit of Certification 3.1 Identity Preserved, Segregation, Mass Balance, 3.2. Book and Claim 4. Definitions 5. Responsibilities 5.1 Head of the Certification
Session 6: WHO Prequalification Programme. Key Process Steps WHO: Medicines UNFPA: Condoms and IUDs
Session 6: WHO Prequalification Programme Key Process Steps WHO: Medicines UNFPA: Condoms and IUDs Session adapted from the WHO training workshop on prequalification and the WHO technical briefing seminar
COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT OF POST-MARKETING SURVEILLANCE STUDIES OF VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/CVMP/044/99-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT
The European regulatory system for medicines and the European Medicines Agency
The European regulatory system for medicines and the European Medicines Agency A consistent approach to medicines regulation across the European Union An agency of the European Union This booklet is intended
Guideline on dossier requirements for Type IA and IB notifications
Guideline on dossier requirements for Type IA and IB notifications In accordance with Regulation (EC) No 726/2004 and Directives 2001/83/EC and 2001/82/EC, a common approach to the procedures for variations
PROJECT MANAGEMENT PLAN HEKLA
MANAGEMENT PLAN HEKLA CONTENT 1. Introduction --------------------------------------------------------------------------- 0 2. Project organisation and management --------------------------------------------
Manual for ITC's clients, 2013. Conformity assessment of ACTIVE IMPLANTABLE MEDICAL DEVICES pursuant to Council Directive 90/385/EEC
Manual for ITC's clients, 2013 Conformity assessment of ACTIVE IMPLANTABLE MEDICAL DEVICES pursuant to Council Directive 90/385/EEC Institute for Testing and Certification, inc., Czech Republic, EU 1.
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL
Ref. Ares(2013)148102-05/02/2013 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products quality, safety and efficacy Brussels, SANCO/D/6/SF/mg/ddg1.d.6(2013)179367
End of consultation (deadline for comments) 14 October 2009. Adoption by Committee for advanced therapies 15 October 2010
15 October 2010 EMA/CAT/418458/2008/corr. Committee for advanced therapies (CAT) Procedural advice on the certification of quality and nonclinical data for small and medium sized enterprises developing
Qualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015
Qualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015 *QP Code of Practice 2008 updated Aug15 Page 1 of 13 Code of Practice for Qualified Persons 1. INTRODUCTION 2.
Rules for the certification of event sustainability management system
Rules for the certification of event sustainability management system In force from 10/09/2014 RINA Services S.p.A. Via Corsica, 12 16128 Genova Tel. +39 010 53851 Fax +39 010 5351000 E-MAIL: [email protected],
Frequently Asked Questions. Unannounced audits for manufacturers of CE-marked medical devices. 720 DM 0701-53a Rev 1 2014/10/02
Frequently Asked Questions Unannounced audits for manufacturers of CE-marked medical devices 720 DM 0701-53a Rev 1 2014/10/02 What is an unannounced audit?... 6 Are unannounced audits part of a new requirement?...
The Formalized Risk Assessment for Excipients A Practical Approach. Frithjof Holtz, IPEC Europe Vice-Chair, Merck
The Formalized Risk Assessment for Excipients A Practical Approach Frithjof Holtz, IPEC Europe Vice-Chair, Merck Presentation Overview Regulatory Background EU FMD and Formalized Risk Assessment Proposal
ASTRAZENECA GLOBAL POLICY QUALITY AND REGULATORY COMPLIANCE
ASTRAZENECA GLOBAL POLICY QUALITY AND REGULATORY COMPLIANCE THIS POLICY OUTLINES THE TOP LEVEL REQUIREMENTS TO SUPPORT PRODUCT QUALITY IN THE DEVELOPMENT, MANUFACTURE AND DISTRIBUTION OF ACTIVE PHARMACEUTICAL
Market withdrawal and suspension of marketing authorisation of medicinal product due to good manufacturing practice noncompliance in India
Market withdrawal and suspension of marketing authorisation of medicinal product due to good manufacturing practice noncompliance in India C-269/13 Acino AG vs. European Commission, LS&R 885 Citeersuggestie:
Pharmacovigilance System Master File (PSMF), QPPV and audits
Federal Agency for Medicines and Health Products (FAMHP) Pharmacovigilance System Master File (PSMF), QPPV and audits Matthijs Nele, PhV Inspector, DG Inspection BRAS - FAMHP/NM/ 1 Content Introduction
Introduction 2. 1. The Role of Pharmacy Within a NHS Trust 3. 2. Pharmacy Staff 4. 3. Pharmacy Facilities 5. 4. Pharmacy and Resources 6
Index Index Section Page Introduction 2 1. The Role of Pharmacy Within a NHS Trust 3 2. Pharmacy Staff 4 3. Pharmacy Facilities 5 4. Pharmacy and Resources 6 5. Prescription Charges 7 6. Communication
TRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP
DISCLAIMER: The EU reserves the right to make subsequent modifications to this text and to complement its proposals at a later stage, by modifying, supplementing or withdrawing all, or any part, at any
Rules for the certification of asset management systems
Rules for the certification of asset management systems In force from 8/09/2014 RINA Services S.p.A. Via Corsica, 12 16128 Genova Tel. +39 010 53851 Fax +39 010 5351000 E-MAIL: [email protected], web: www.rina.org
Reflection paper on the Use of Interactive Response Technologies (Interactive Voice/Web Response Systems) in Clinical Trials
1 2 3 5 August 2011 EMA/INS/GCP/600788/2011 Compliance and Inspection 4 5 6 7 Reflection paper on the Use of Interactive Response Technologies (Interactive Voice/Web Response Systems) in Clinical Trials
"How to do"- Document ACTIVE PHARMACEUTICAL INGREDIENTS COMMITTEE
Cefic/APIC "How to do" Document ACTIVE PHARMACEUTICAL INGREDIENTS COMMITTEE GDP for APIs: How to do Document Interpretation of the WHO Guideline GOOD TRADE AND DISTRIBUTION PRACTICES FOR PHARMACEUTICAL
State of Control Over the Lifecycle and Process Validation (New and Legacy Products)
State of Control Over the Lifecycle and Process Validation (New and Legacy Products) Grace McNally Branch Chief (acting), Regulatory Policy and Collaboration Branch FDA/CDER/Office of Compliance ICH Q10,
23. The quality management system
23. The quality management system Version 2.0 On this page: Mandatory requirements: Extracts from the HFE Act Extracts from licence conditions HFEA guidance: Definition of the quality management system
There is no Silver Bullet to complying with the US FDA GMPs by Alan Schwartz
There is no Silver Bullet to complying with the US FDA GMPs by Alan Schwartz Recently, we participated in a seminar on United States (US) Food and Drug Administration (FDA) regulations to the Hebei Pharmaceutical
ASSESSMENT OF QUALITY RISK MANAGEMENT IMPLEMENTATION
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 038-1 26 March 2012 AIDE-MEMOIRE ASSESSMENT OF QUALITY RISK MANAGEMENT IMPLEMENTATION PIC/S March 2012 Reproduction
Action plan for the implementation of the Germanwings Task Force recommendations
Action plan for the implementation of the Germanwings Task Force recommendations Version 1 7 October 2015 Page 1 of 9 1 Executive summary The Germanwings tragedy reminded the international aviation community
Pharmaceutical Auditor Training
www.nsf.org Formerly NSF-DBA The right people. The right solution. The first time. Pharmaceutical or Training Pharmaceutical GMP s and Self-Inspections PQMS or/lead or Training Course A17638 Why Choose
Certification rules for the mark
Identification No.: NF148 Version No.: 2 Date of approval: 13/12/2012 Edition date: 19/12/2012 Certification rules for the mark Validation of analysis methods Application to water analysis APPENDIX Validation,
The Management of Pharmaceuticals in the Environment (PIE) FAQ. Key questions and answers. Q: How do pharmaceuticals get into the environment?
The Management of Pharmaceuticals in the Environment (PIE) FAQ Key questions and answers Q: How do pharmaceuticals get into the environment? A: Like many foods and supplements that are consumed by humans
Spillemyndigheden s Certification Programme Change Management Programme
SCP.06.00.EN.2.0 Table of contents Table of contents... 2 1 Introduction... 4 1.1 Spillemyndigheden s certification programme... 4 1.2 Objectives of the change management programme... 4 1.3 Scope of this
Guideline on good pharmacovigilance practices (GVP)
9 April 2013 EMA/816573/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module II Pharmacovigilance system master file (Rev 1) Draft of first version finalised by the Agency in collaboration
Introduction to Q10 Pharmaceutical Quality System
ICH-GCG Asean Training Workshop on ICH Guidelines Q8,Q9 and Q10 (New Paradigm) Introduction to Q10 Pharmaceutical Quality System Georges FRANCE, Q- IWG Kuala Lumpur, Malaysia 26-28 July 2010 International
Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle
Quality Risk Management 11 November 2011 Galway, Ireland Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle Overview Regulatory
John Keel, CPA State Auditor. An Audit Report on Inspections of Compounding Pharmacies at the Board of Pharmacy. August 2015 Report No.
John Keel, CPA State Auditor An Audit Report on Inspections of Compounding Pharmacies at the Board of Pharmacy Report No. 15-039 An Audit Report on Inspections of Compounding Pharmacies at the Board of
CONTENT OF BOOKLET. 4 Objective & Scope 5 Safe Management Practices. 6. Training. 8. Emergency Response. 9. Control of Operations. 10.
ISSUE 1 - April 2002 Recommendations on Safety, Health and Environmental Management Practices for Logistics Service Providers CONTENT OF BOOKLET 4 Objective & Scope 5 Safe s 1. Commitment & Awareness of
Harmonizing Change Control Processes Globally
Quality & Compliance Associates, LLC Harmonizing Change Control Processes Globally President Quality & Compliance Associates, LLC When We Deal In A Global Environment, How Do We Design A System That Addresses
20 & 21 October 2005 Clinical trials Risk issues within a wider Europe. Adrien Collovray Marsh Life Science Conference 2005 Berlin, Germany
20 & 21 October 2005 Clinical trials Risk issues within a wider Europe Adrien Collovray Life Science Conference 2005 Berlin, Germany Clinical trials EC Directive on clinical trials Insurance Requirements
Education, Audiovisual and Culture Executive Agency Financial Information Kit
Education, Audiovisual and Culture Executive Agency Financial Information Kit Introduction This financial information kit helps you avoid financial pitfalls in managing your project This Financial Information
Application form. Application Checklist. Application process. Eligibility criteria. Energy Saving Scotland Small Business Loans
Energy Saving Scotland Small Business Loans ESSSBL0512 Helping Scottish businesses reduce their energy costs Application form Eligibility criteria The scheme is aimed at Scottish businesses that fall within
Annex 2: Rules and Procedures for the Swiss-Polish Cooperation Programme
Annex 2: Rules and Procedures for the Swiss-Polish Cooperation Programme Annex 2 is an integral part of the Framework Agreement between the Swiss Federal Council and the Government of the Republic of Poland
General Rules for the Certification of Management Systems Code: RG
General Rules for the Certification of Management Systems Code: RG Drafted on: 1 April 2012 Effective from: 1 October 2012 TABLE OF CONTENTS CHAPTER TITLE PAGE CHAPTER 1 GENERAL 3 CHAPTER 2 REFERENCE STANDARD
PROCEDURE FOR PREPARING GCP INSPECTIONS REQUESTED BY THE EMEA. GCP Inspectors Working Group
European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197228/2005 Procedure no.: INS/GCP/2 PROCEDURE FOR PREPARING GCP INSPECTIONS REQUESTED BY THE EMEA GCP Inspectors Working Group
TERMS OF SUPPLY FOR EDQM (COUNCIL OF EUROPE) EVENTS
1. GENERAL PROVISIONS These terms of supply apply only to the events organised by the European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, Strasbourg, France, herein
SUMMARY AUDIT REPORT DIRECTORATE OF CIVIL AVIATION OF MOROCCO
ICAO Universal Safety Oversight Audit Programme SUMMARY AUDIT REPORT DIRECTORATE OF CIVIL AVIATION OF MOROCCO (Rabat, 26 October to 3 November 1999) INTERNATIONAL CIVIL AVIATION ORGANIZATION ICAO UNIVERSAL
Konformitätsbewertung 3.9 B 17. Guidance for Notified Bodies auditing suppliers to medical device manufacturers
Antworten und Beschlüsse des EK-Med Konformitätsbewertung 3.9 B 17 Guidance for Notified Bodies auditing suppliers to medical device manufacturers Herkunft Notified Body Operations Group Quellen NBOG BPG
INTEROPERABILITY UNIT
INTEROPERABILITY UNIT MODULES FOR THE PROCEDURES FOR ASSESSMENT OF CONFORMITY, SUITABILITY FOR USE AND EC VERIFICATION TO BE USED IN THE TECHNICAL SPECIFICATIONS FOR INTEROPERABILITY Reference: Version
Smart Meters Programme Schedule 2.5. (Security Management Plan) (CSP South version)
Smart Meters Programme Schedule 2.5 (Security Management Plan) (CSP South version) Schedule 2.5 (Security Management Plan) (CSP South version) Amendment History Version Date Author Status v.1 Signature
Align Technology. Data Protection Binding Corporate Rules Processor Policy. 2014 Align Technology, Inc. All rights reserved.
Align Technology Data Protection Binding Corporate Rules Processor Policy Confidential Contents INTRODUCTION TO THIS POLICY 3 PART I: BACKGROUND AND ACTIONS 4 PART II: PROCESSOR OBLIGATIONS 6 PART III:
Track & Trace. The Distribution Chain to the EU and within the EU
ECA ACADEMY The new GDP and Track & Trace Regulations in Europe Jersey City, NJ (New York City Metro Area), USA July 14-15, 2015 A conference organised by the ECA Academy and the European QP Association
European Forum for Good Clinical Practice Audit Working Party
European Forum for Good Clinical Practice Audit Working Party REVISION OF THE ENGAGE 1 AUDITING GUIDELINE. AN OPTIONAL GUIDELINE FOR GCP COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS AUDITING This document
GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group [email protected]
GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group [email protected] Common Misconception Good Laboratory Practices 1) A quality system concerned with the organizational process
